

# Influenza A Virus Hemagglutinin (C102): sc-52025

## BACKGROUND

Influenza A viruses are negative sense, single-stranded, segmented RNA viruses which are hosted by birds, but may infect several species of mammals. All known subtypes are endemic in birds. The subtypes of Influenza A are classified based on the combination of the virus coat glycoproteins hemagglutinin (HA) and neuraminidase (NA) subtypes. There are 16 different HA antigens (H1-H16) and nine different NA antigens (N1-N9) for Influenza A. The extent of infection into host organisms is determined by HA, which interacts with cell surface proteins containing oligosaccharides with terminal sialyl residues.

## REFERENCES

- Green, N., et al. 1982. Immunogenic structure of the influenza virus hemagglutinin. *Cell* 28: 477-487.
- Gething, M.J., et al. 1986. Expression of wild-type and mutant forms of influenza hemagglutinin: the role of folding in intracellular transport. *Cell* 46: 939-950.
- Webster, R.G. and Rott, R. 1987. Influenza virus A pathogenicity: the pivotal role of hemagglutinin. *Cell* 50: 665-666.
- Wilson, I.A. and Cox, N.J. 1990. Structural basis of immune recognition of influenza virus hemagglutinin. *Annu. Rev. Immunol.* 8: 737-771.
- Skehel, J.J. and Wiley, D.C. 2000. Receptor binding and membrane fusion in virus entry: the influenza hemagglutinin. *Annu. Rev. Biochem.* 69: 531-569.

## SOURCE

Influenza A Virus Hemagglutinin (C102) is a mouse monoclonal antibody raised against purified Influenza virus A strain H1N1.

## PRODUCT

Each vial contains 100 µg IgG<sub>1</sub> kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

## APPLICATIONS

Influenza A Virus Hemagglutinin (C102) is recommended for detection of hemagglutinin of H1N1 serotype of Influenza A Virus origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000) and immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500).

Molecular Weight of Influenza A Virus Hemagglutinin: 28 kDa.

## RECOMMENDED SUPPORT REAGENTS

To ensure optimal results, the following support reagents are recommended: 1) Western Blotting: use m-IgGκ BP-HRP: sc-516102 or m-IgGκ BP-HRP (Cruz Marker): sc-516102-CM (dilution range: 1:1000-1:10000), Cruz Marker™ Molecular Weight Standards: sc-2035, UltraCruz® Blocking Reagent: sc-516214 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use m-IgGκ BP-FITC: sc-516140 or m-IgGκ BP-PE: sc-516141 (dilution range: 1:50-1:200) with UltraCruz® Mounting Medium: sc-24941 or UltraCruz® Hard-set Mounting Medium: sc-359850.

## STORAGE

Store at 4° C, **\*\*DO NOT FREEZE\*\***. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

## SELECT PRODUCT CITATIONS

- Co, M.D., et al. 2009. *In vitro* evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. *Vaccine* 27: 319-327.
- LeBouder, F., et al. 2010. Plasminogen promotes Influenza A Virus replication through an annexin 2-dependent pathway in the absence of neuraminidase. *J. Gen. Virol.* 91: 2753-2761.
- Motard, J., et al. 2011. A novel ribozyme-based prophylaxis inhibits Influenza A Virus replication and protects from severe disease. *PLoS ONE* 6: e27327.
- Adamson, A.L., et al. 2011. A *Drosophila* model for genetic analysis of influenza viral/host interactions. *Genetics* 189: 495-506.
- Berri, F., et al. 2013. Plasminogen controls inflammation and pathogenesis of influenza virus infections via fibrinolysis. *PLoS Pathog.* 9: e1003229.
- Khoufache, K., et al. 2013. PAR1 contributes to Influenza A Virus pathogenicity in mice. *J. Clin. Invest.* 123: 206-214.
- Uranowska, K., et al. 2014. Hemagglutinin stalk domain from H5N1 strain as a potentially universal antigen. *Acta Biochim. Pol.* 61: 541-550.
- Checconi, P., et al. 2015. Redox proteomics of the inflammatory secretome identifies a common set of redoxins and other glutathionylated proteins released in inflammation, influenza virus infection and oxidative stress. *PLoS ONE* 10: e0127086.
- Leu, C.H., et al. 2015. Kallistatin ameliorates influenza virus pathogenesis by inhibition of kallikrein-related peptidase 1-mediated cleavage of viral hemagglutinin. *Antimicrob. Agents Chemother.* 59: 5619-5630.
- Chen, S.C., et al. 2017. Zinc finger-containing cellular transcription corepressor ZBTB25 promotes influenza virus RNA transcription and is a target for zinc ejector drugs. *J. Virol.* 91 pii: e00842-17.
- Lee, E.B., et al. 2019. Attachment of flagellin enhances the immunostimulatory activity of a hemagglutinin-ferritin nano-cage. *Nanomedicine* 17: 223-235.
- Chen, X., et al. 2019. Maduramicin induces apoptosis through ROS-PP5-JNK pathway in skeletal myoblast cells and muscle tissue. *Toxicology* 424: 152239.
- Mandon, E.D., et al. 2019. Novel calixarene-based surfactant enables low dose split inactivated vaccine protection against influenza infection. *Vaccine* 38: 278-287.
- Jeong, H., et al. 2020. A multiligand architectural photosensitizer that targets hemagglutinin on envelope of influenza virus for photodynamic inactivation. *Small* 16: e2000556.

## RESEARCH USE

For research use only, not for use in diagnostic procedures.